Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease
- 17 September 2004
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 63 (1) , 19-28
- https://doi.org/10.1002/pros.20154
Abstract
BACKGROUND Although up to 30% of men who undergo radical prostatectomy for clinically organ‐confined prostate cancer will relapse with disseminated disease, currently it is not possible to predict these patients. METHODS Androgen receptor (AR) immunoreactivity in stromal and epithelial compartments of tumor foci was evaluated by video image analysis in 53 radical prostatectomy specimens. Kaplan–Meier and Cox Regression analyses were used to determine whether AR immunostaining was related to rate and risk of relapse, respectively. RESULTS Ninety‐eight percent (52/53) of the tumors contained AR positive malignant epithelial cells. Kaplan–Meier analysis indicated that patients with high AR levels (>64% AR positive nuclear area) in the malignant epithelial cells or low AR levels (≤45% AR positive nuclear area) in the peritumoral stroma cells, were more likely to relapse earlier following radical prostatectomy. The shortest time to relapse and the highest relapse rate was for patients with both high AR in the malignant epithelial cells and low AR in the peritumoral stromal cells. CONCLUSIONS These findings suggest that AR is an important determinant of disease relapse in early stage prostate cancer, and that altered AR levels in the malignant epithelial cells or in the peritumoral stroma is indicative of non‐organ confined prostate cancer.Keywords
This publication has 41 references indexed in Scilit:
- Androgen receptors in prostate cancer.Endocrine-Related Cancer, 2002
- VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION AND TUMOR ANGIOGENESIS ARE REGULATED BY ANDROGENS IN HORMONE RESPONSIVE HUMAN PROSTATE CARCINOMA: : EVIDENCE FOR ANDROGEN DEPENDENT DESTABILIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR TRANSCRIPTSJournal of Urology, 2001
- Contribution of the Androgen Receptor to Prostate Cancer Predisposition and ProgressionCancer and Metastasis Reviews, 2001
- Treatment Options in Androgen-Independent Prostate CancerCancer Investigation, 1999
- Tissue Prostate-Specific Antigen and Androgen Receptor Immunoreactivity in Prostate Cancer Biopsies before, during and after Neo-Adjuvant Androgen Deprivation Followed by RadiotherapyEuropean Urology, 1999
- Molecular Action of Androgen in the Normal and Neoplastic ProstatePublished by Elsevier ,1998
- Regulation of Androgen ActionPublished by Elsevier ,1998
- Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinomaCancer, 1996
- Image analysis of androgen receptor immunostaining in metastatic prostate cancer heterogeneity as a predictor of response to hormonal therapyCancer, 1993
- Androgen receptors in endocrine‐therapy‐resistant human prostate cancerInternational Journal of Cancer, 1991